These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35508594)

  • 1. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.
    Goulooze SC; Heerspink HJL; van Noort M; Snelder N; Brinker M; Lippert J; Eissing T
    Clin Pharmacokinet; 2022 Jul; 61(7):1013-1025. PubMed ID: 35508594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
    Eissing T; Goulooze SC; van den Berg P; van Noort M; Ruppert M; Snelder N; Garmann D; Lippert J; Heinig R; Brinker M; Heerspink HJL
    Diabetes Obes Metab; 2024 Mar; 26(3):924-936. PubMed ID: 38037539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
    van den Berg P; Ruppert M; Mesic E; Snelder N; Seelmann A; Heinig R; Joseph A; Garmann D; Lippert J; Eissing T
    Clin Pharmacokinet; 2022 Mar; 61(3):439-450. PubMed ID: 34773606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
    Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
    Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
    Snelder N; Heinig R; Drenth HJ; Joseph A; Kolkhof P; Lippert J; Garmann D; Ploeger B; Eissing T
    Clin Pharmacokinet; 2020 Mar; 59(3):359-370. PubMed ID: 31583611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
    Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Amod A; Marre M; Joseph A; Lage A; Scott C; Bakris GL;
    Diabetes Obes Metab; 2022 Jan; 24(1):125-134. PubMed ID: 34580995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
    Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
    Goulooze SC; Snelder N; Seelmann A; Horvat-Broecker A; Brinker M; Joseph A; Garmann D; Lippert J; Eissing T
    Clin Pharmacokinet; 2022 Mar; 61(3):451-462. PubMed ID: 34786651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
    Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
    Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
    Koya D; Anker SD; Ruilope LM; Rossing P; Liu Z; Lee BW; Lee CT; Scott C; Kolkhof P; Lawatscheck R; Wang L; Joseph A; Pitt B;
    Am J Nephrol; 2023; 54(9-10):370-378. PubMed ID: 37708857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
    Green JB; Mottl AK; Bakris G; Heerspink HJL; Mann JFE; McGill JB; Nangaku M; Rossing P; Scott C; Gay A; Agarwal R
    Nephrol Dial Transplant; 2023 Mar; 38(4):894-903. PubMed ID: 35700142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
    Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.
    Ghosal S; Sinha B
    Front Endocrinol (Lausanne); 2023; 14():1114894. PubMed ID: 36742404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
    Rossing P; Burgess E; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Gillard P; MacIsaac RJ; Wainstein J; Joseph A; Brinker M; Roessig L; Scott C; Bakris GL;
    Diabetes Care; 2022 Apr; 45(4):888-897. PubMed ID: 35061867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.